Research programme: interleukin-17 peptide antagonists - Protagonist Therapeutics
Alternative Names: Oral IL-17; Research programme: IL-17 peptide antagonists - Protagonist TherapeuticsLatest Information Update: 26 Apr 2024
At a glance
- Originator Protagonist Therapeutics
- Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Peptides; Skin disorder therapies
- Mechanism of Action Interleukin 17 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Hidradenitis suppurativa; Plaque psoriasis; Psoriatic arthritis; Spondylarthritis